{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:35:45Z","timestamp":1790224545534,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In recent years, many new treatments for relapsed\/refractory (R\/R) multiple myeloma (MM) have improved patient prognosis, but the prognosis of patients with extramedullary MM is still particularly poor. Therefore, more efficacious therapies and novel strategies are urgently needed for these patients. The aim of this study was to observe and compare the efficacy and safety of humanized anti-B cell maturation antigen (anti-BCMA) chimeric antigen receptor (CAR) T cell therapy in R\/R MM patients with and without extramedullary disease. Seven R\/R MM patients with extramedullary disease and 13 without extramedullary disease received humanized anti-BCMA CAR T cell therapy. The overall response rate was not different between patients with and without extramedullary disease. There was no difference in the progression-free survival (PFS) or overall survival (OS) rates between the two groups at 180 days, but the PFS and OS rates in patients with extramedullary disease were lower at 360 days than those in patients without extramedullary disease. Although some patients with extramedullary disease experienced further disease progression, their M protein level did not increase. We did not see this change trend of M protein in patients without extramedullary disease. However, this was not observed in patients without extramedullary disease. Among patients who responded to CAR T cell therapy, the grades of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxic syndrome (ICANS) were much higher among patients with extramedullary disease. In summary, R\/R MM patients with extramedullary disease could benefit from humanized anti-BCMA CAR T cell therapy in the short term, although the CRS and ICANS grades were much higher in patients with extramedullary disease. Therefore, anti-BCMA CAR T cell therapy allows for a remission time for R\/R MM patients with extramedullary disease, which could be maintained by bridging hematopoietic stem cell transplantation, radiotherapy, and other therapies.<\/jats:p><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>http:\/\/www.chictr.org.cn\/index.aspx<\/jats:uri>, identifiers ChiCTR1800017051 and ChiCTR2000033925.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.720571","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T04:25:38Z","timestamp":1628137538000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Haobin","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.1742","article-title":"Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial","volume":"36","author":"Dimopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-791228","article-title":"Ixazomib Significantly Prolongs Progression-Free Survival in High-Risk Relapsed\/Refractory Myeloma Patients","volume":"130","author":"Avet-Loiseau","year":"2017","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I Treat Myeloma With New Agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-653261","article-title":"How I Treat High-Risk Myeloma","volume":"126","author":"Lonial","year":"2015","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.178434","article-title":"Impact of Extramedullary Disease in Patients With Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.740562","article-title":"Extramedullary Multiple Myeloma","volume":"54","author":"Weinstock","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary Disease Portends Poor Prognosis in Multiple Myeloma and Is Over-Represented in High-Risk Disease Even in the Era of Novel Agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary Multiple Myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-Targeted CAR T-Cell Therapy Plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1393668","article-title":"CAR T Cell Therapy for Multiple Myeloma: Where are We Now and Where are We Headed","volume":"59","author":"Ghosh","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of Multiple Myeloma in the Relapsed\/Refractory Patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2438","DOI":"10.7759\/cureus.2438","article-title":"Disease Milestones Through Bibliometric Analysis of the Top 100 Cited Articles in Multiple Myeloma","volume":"10","author":"Latif","year":"2018","journal-title":"Cureus"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3390\/cancers11122024","article-title":"Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma","volume":"11","author":"Hosen","year":"2019","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B Cell Maturation Antigen-Specific CAR T Cells are Clinically Active in Multiple Myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25428","article-title":"Chimeric Antigen Receptor T Cell Immunotherapy for Multiple Myeloma: A Review of Current Data and Potential Clinical Applications","volume":"94","author":"Adaniya","year":"2019","journal-title":"Am J Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Multiple Myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated With Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Tr"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple Myeloma","volume":"385","author":"Rollig","year":"2015","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00531.x","article-title":"Plasmacytoma Relapses in the Absence of Systemic Progression Post-High-Dose Therapy for Multiple Myeloma","volume":"75","author":"Terpos","year":"2005","journal-title":"Eur J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/%25x","article-title":"Different Patterns of Relapse After Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Clinical Results of 280 Cases From the Spanish Registry","volume":"87","author":"Alegre","year":"2002","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12325-011-0079-0","article-title":"Multiple Myeloma With Extramedullary Disease","volume":"28","author":"Oriol","year":"2011","journal-title":"Adv Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I Treat Extramedullary Myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach","volume":"29","author":"Blade","year":"2011","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp329","article-title":"Incidence, Presenting Features and Outcome of Extramedullary Disease in Multiple Myeloma: A Longitudinal Study on 1003 Consecutive Patients","volume":"21","author":"Varettoni","year":"2010","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-007-9108-4","article-title":"Extravasation and Homing Mechanisms in Multiple Myeloma","volume":"25","author":"Vande Broek","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.094409","article-title":"Soft-Tissue Extramedullary Multiple Myeloma Prognosis Is Significantly Worse in Comparison to Bone-Related Extramedullary Relapse","volume":"99","author":"Pour","year":"2014","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219295","article-title":"A Real World Multicenter Retrospective Study on Extramedullary Disease From Balkan Myeloma Study Group and Barcelona University: Analysis of Parameters That Improve Outcome","volume":"105","author":"Beksac","year":"2020","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705982","article-title":"Extramedullary Relapses After Allogeneic Non-Myeloablative Stem Cell Transplantation in Multiple Myeloma Patients do Not Negatively Affect Treatment Outcome","volume":"41","author":"Minnema","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404085","article-title":"Reduced-Intensity Conditioning Allogeneic Transplantation Is Associated With a High Incidence of Extramedullary Relapses in Multiple Myeloma Patients","volume":"20","author":"Perez-Simon","year":"2006","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-Cell Maturation Antigen in Multiple Myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.21037\/atm.2018.11.14","article-title":"BCMA CAR T-Cell Therapy Arrives for Multiple Myeloma: A Reality","volume":"6","author":"Cho","year":"2018","journal-title":"Ann Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of Chimeric Antigen Receptor T Cells: Recognition and Management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","article-title":"Cytokine Release Syndrome: Grading, Modeling, and New Therapy","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of Cytokine Release Syndrome and Neurotoxicity Related to CAR-T Cell Therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002550","article-title":"Neurotoxicity-CAR T-Cell Therapy: What the Neurologist Needs to Know","volume":"20","author":"Neill","year":"2020","journal-title":"Pract Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric Antigen Receptor T-Cell Therapy - Assessment and Management of Toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14680","article-title":"Neurological Toxicities and Coagulation Disorders in the Cytokine Release Syndrome During CAR-T Therapy","volume":"181","author":"Mei","year":"2018","journal-title":"Br J Haematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.720571\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T04:25:41Z","timestamp":1628137541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.720571\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2021.720571"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.720571","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"article-number":"720571"}}